Prescription drug · NDA
Condylox (Podofilox) NDC 0023-6118
Podofilox 5 mg/g · Gel · Topical · Allergan, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0023-6118-03 | 00023611803 | 3.5 g in 1 TUBE, WITH APPLICATOR (0023-6118-03)Marketed from Mar 13, 1997 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Condylox
- Generic name (nonproprietary)
- podofilox
- Active ingredients
- Podofilox — 5 mg/g
- Dosage form
- Gel
- Route
- Topical
- Labeler
- Allergan, Inc.NDC labeler code 0023
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 020529
- Marketing start
- Marketing end
- Other FDA classes
- Decreased Mitosis (Physiologic effect)
- Identifiers
- Product ID 0023-6118_9f2892be-8330-4fd1-930e-b4d204df4e03SPL ID 9f2892be-8330-4fd1-930e-b4d204df4e03SPL set ID 032e4bcb-b1ed-4029-b2a6-e92f3bf5cc37RxCUI 312466, 351750UNII L36H50F353UPC 0300236118037
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400023611803followed by a unit qualifier and the quantityPackage 00023-6118-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Condylox Gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and "Bowenoid papulosis" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with Condylox Gel 0.5%.
Excerpt only. Read the full label for complete information.
About NDC 0023-6118
- What is NDC 0023-6118?
- 0023-6118 is the product NDC for Condylox (podofilox), Podofilox 5 mg/g gel, listed with the FDA by Allergan, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Condylox (Podofilox).
- What is the active ingredient?
- Podofilox.
- Who is the labeler?
- Allergan, Inc., NDC labeler code 0023. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Condylox?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.